NHF's research grants support a variety of disciplines and levels of expertise.
PrintFriendly
-
NHF’s Current Research Grant Cycle
-
Two New MASAC Documents Issued
The two recommendations address gene therapy clinical trials, and use of emicizumab-kxwh.
-
Inhibitor Chapter Updated in Nurses’ Guide to Bleeding Disorders
This chapter includes new product approvals and Guelcher explains that ITI could be the solution to eradicate the inhibitor itself.
-
uniQure Announces Initial Data Showing Positive Early Results from Hemophilia B Gene Therapy
UniQure recently announced initial clinical data from patients treated in an open-label phase IIb dose-confirmation study of AMT-061, the company’s investigational gene therapy treatment for patients with severe and moderately severe hemophilia B.
-
Accredited Webinars on Management of Women with Bleeding Disorders Still Available
NHF, Impact Education and the Postgraduate Institute for Medicine offers accredited educational opportunties for healthcare providers on managing and treating females with bleeding disorders.
-
NHF 70th: The “Transformative” Era of Therapy
Stacy E. Croteau, MD, MMS, pediatric hematologist and clinical researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, shares her thoughts on 'the now and the next' in bleeding disorders treatment.
-
HANDI Highlights: Pain Management Resources
HANDI hopes that you find these pain management resources helpful as we approach the busy holiday season!
-
Supply Delays for CSL Behring’s Mononine®
CSL Behring is experiencing intermittent supply delays of Mononine®, the company’s human plasma derived factor IX product for treatment of patients with hemophilia B.